Evidence map›Paper›PMID 41009470›Full record

ArticleInternational journal of molecular sciences2025

A Murine Model of Glioblastoma Initiating Cells and Human Brain Organoid Xenograft for Photodynamic Therapy Testing.

Alejandra Mosteiro, Diouldé Diao, Carmen Bedia, Leire Pedrosa, Gabriela Ailén Caballero, Iban Aldecoa, Mar Mallo, Francesc Solé, Ana Sevilla, Abel Ferrés and 6 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alejandra MosteiroLaboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain.
Diouldé DiaoLaboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain.ORCID 0000-0003-4051-9256
Carmen BediaInstitute of Environmental Assessment and Water Research (IDAEA-CSIC), 08034 Barcelona, Spain.ORCID 0000-0003-4584-5843
Leire PedrosaLaboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain.ORCID 0000-0002-1852-4975
Gabriela Ailén CaballeroDepartment of Pathology, Biomedical Diagnostic Center, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-0739-4896
Iban AldecoaDepartment of Pathology, Biomedical Diagnostic Center, Hospital Clínic of Barcelona, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-5774-7453
Mar MalloMicroarrays Unit, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.ORCID 0000-0001-7741-498X
Francesc SoléMicroarrays Unit, Institut de Recerca Contra la Leucèmia Josep Carreras (IJC), ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.ORCID 0000-0002-3251-2161
Ana SevillaInstitute of Biomedicine, University of Barcelona (IBUB), 08036 Barcelona, Spain.ORCID 0000-0002-9251-4759
Abel FerrésDepartment of Neurosurgery, Hospital Clínic de Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-0003-3235
Gloria CabreraDepartment of Neurosurgery, Hospital Clínic de Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.
Marta Muñoz-TuduríLaboratorios Gebro Pharma S.A., 08022 Barcelona, Spain.ORCID 0009-0002-2184-4061
Marc CentellasLaboratorios Gebro Pharma S.A., 08022 Barcelona, Spain.
Estela PinedaDepartment of Oncology, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain.ORCID 0000-0003-2128-747X
Àngels Sierra JiménezLaboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain.
José Juan González SánchezLaboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona-FCRB, 08036 Barcelona, Spain.ORCID 0000-0001-7589-6575

Funding

Asociación Española Contra el Cáncer GCTRA16015SEDAEuropean Union CNS2023-144709Gebro Pharma (Spain) LGP17-19Generalitat de Catalunya 2021SGR00453 and 2021-SGR-01423Josep Carreras Leukaemia Research Institute Not applicable
6 · The paper itself

Abstract

Glioblastoma (GB) is one of the most aggressive brain tumors, characterized by high infiltrative capacity that enables tumor cells to invade healthy brain tissue and evade complete surgical resection. This invasiveness contributes to resistance against conventional therapies and a high recurrence rate. Strategies capable of eliminating residual tumor cells are urgently needed. Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA), an FDA- and EMA-approved compound, induces selective accumulation of the photosensitizer protoporphyrin IX (PpIX) in metabolically active tumor cells, enabling targeted cytotoxicity through light activation. A major limitation to its clinical application is the unclear variation in the cytotoxic effect of PDT according to individual tumoral differences. In this study, we propose and validate an in vivo model of patient-derived GB initiating cells (GICs) and brain organoids to test the effects of PDT. First, patient-derived GICs were molecularly characterized by flow cytometry and copy number variation profiling using OncoScan CNV Assays, then co-cultured with human brain organoids to generate a hybrid model recapitulating key aspects of the tumor microenvironment. 5-ALA photodynamic therapy (PDT) efficacy was assessed in vitro by GFP-based viability measurements, LDH release assays, and TUNEL staining. Then, a murine model was generated to study PDT in vivo, based on a heterotopic (renal subcapsular engraftment) xenograft of the GICs-human brain organoid co-culture. PDT was tested in the model; in each subject, one kidney tumoral engraftment was treated and the contralateral served as a control. Immunofluorescence analysis was used to study the cell composition of the brain organoid-tumoral engraftment after PDT, and the effects on non-GIC cells. The antitumoral effect was determined by the degree of cell death analysis with the TUNEL technique. The GICs-brain organoid co-culture resulted in tumoral growth and infiltration both in vitro and in vivo. The pattern of growth and infiltration varied according to the tumoral genetic profile. 5-ALA PDT resulted in a reduction in the number of GICs and an increase in apoptotic cells in all four lines tested in vitro. A correlation was found between the induced phototoxicity in vivo with the molecular typification of GICs cell lines in vitro. There were no changes in the number or distribution of neuronal cells after the application of PDT, while a reduction in active astrocytes was observed. 5-ALA PDT could be effective in eradicating GICs with a heterogeneous molecular profile. The hybrid human-murine model presented here could be useful in investigating adjuvant therapies in GB, under the concept of personalized medicine.

Indexed as

Brain NeoplasmsGlioblastomaNeoplastic Stem CellsOrganoidsPhotochemotherapyAminolevulinic AcidAnimalsBrainCell Line, TumorDisease Models, AnimalHumansMicePhotosensitizing AgentsProtoporphyrinsXenograft Model Antitumor AssaysAminolevulinic AcidPhotosensitizing Agentsprotoporphyrin IXProtoporphyrins5-ALAglioblastomamodelorganoidphotodynamic therapy

Identifiers

PMID41009470
PMCPMC12470220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.